Entrada Therapeutics Stock
| Detail | Data |
|---|---|
| Volume (24h): | 288,395 shares |
| P/E Ratio: | 13.10 |
| Forward P/E: | -2.41 |
| EPS: | 0.58 USD |
| Forward EPS: | -3.15 USD |
| Number of Shares: | 37,953,400 shares |
| Market Capitalization: | 288,445,824.00 USD |
Dividend
| Dividend | Value |
|---|---|
| Dividend Amount | According to our data, the company Entrada Therapeutics does not currently pay dividends. |
| Annual Yield %: | - |
| Ex-dividend Date: | - |
| 5-Year Avg Yield %: | - |
| Payout Ratio: | - |
| Last Dividend Value: | - |
| Last Dividend Date: | - |
Analyst Forecast
| Analysts | Recommendation |
|---|---|
| Issued Recommendation: | According to our data, the recommendation for Entrada Therapeutics stock is: strong_buy |
| Number of Analysts: | 3 |
| Highest Target Price: | 30 USD |
| Lowest Target Price: | 20 USD |
| Median Target Price: | 21 USD |
Fundamental Indicators
| Indicator | Data |
|---|---|
| Total Revenue: | 172,220,000.00 USD |
| Net Income: | 24,781,000.00 USD |
| Price-to-Book (P/B): | 0.64 |
| PEG Ratio: | / |
| Exchange: | NasdaqGM |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Number of Employees: | 177 |
| Country: | United States |
Where to Buy Entrada Therapeutics Stock?
You can purchase Entrada Therapeutics stock on the NasdaqGM under the ticker symbol: TRDA. Several stock brokers or banks offer trading services for these stocks. Popular stock brokers like XTB and eToro allow you to buy real stocks and ETFs with zero or minimal commissions. Banks usually charge higher fees. Remember, investing in stocks involves risks, so it's important to carefully consider your financial situation and investment goals.
Real stocks and ETFs. Low minimum deposit, only 50 EUR. Option to copy trades. Advanced stock analysis and free education.
Real stocks and ETFs + free demo account. Low fees + fast customer support. More than 5,200 instruments available for trading. Free training and education. Regular live streams on YouTube.
More Information on Entrada Therapeutics Stock
| Indicator | Value |
|---|---|
| Company Revenue: | 172,220,000.00 USD |
| EBITDA: | 7,893,000.00 USD - Positive EBITDA indicates profitable operations before interest, taxes, depreciation, and amortization. |
| Earnings Per Share: | 0.58 USD |
| Book Value Per Share: | 11.84 USD |
| Total Cash: | 382,515,008.00 USD |
| Total Cash per Share: | 10.85 USD |
| Total Debt: | 56,997,000.00 USD |
| Debt to Equity Ratio: | 0.14 |
| Quick Ratio | 21.00 |
| Current Ratio | 21.88 |
| Free Cash Flow | -65,478,500.00 USD |
| Operating Cash Flow | -54,545,000.00 USD |
| Gross Margins | 25.23 % |
| EBITDA Margins | 4.58 % |
| Operating Margins | -105.99 % |
| Profit Margins | 14.39 % |
| Return on Assets | 0.5 % |
| Return on Equity | 7.2 % |
| Earnings Growth (1 year) | - |
| Revenue Growth (1 year) | -65.2 % |
| Quarterly Earnings Year-over-Year Growth | - |
| Market Capitalization | 288,445,824.00 USD |
| Enterprise Value | -57,567,512.00 USD |
| EV/Revenue | -0.334 |
| EV/EBITDA | -7.293 |
| Float Shares | 18,649,706 shares |
| Shares Outstanding | 37,953,400 shares |
| Held Percent Insiders | 0.12 % |
| Held Percent Institutions | 80.19 % |
| Shares Short | 1,055,797 |
| Shares Short Prior Month | 1,098,052 |
| Date Short Interest | 2025-05-15 |
| Short Percentage of Total Shares | 2.78 % |
| Short Ratio | 7.68 |
| Beta | 0.03 |
| Short Percentage of Float | 5.14 % |
| Implied Shares Outstanding | 37,953,400 |
Frequently Asked Questions (FAQ)
According to our data, the company Entrada Therapeutics does not pay dividends yet, even in 2025.
Entrada Therapeutics shares are traded on the NasdaqGM stock exchange under the ticker: TRDA. You can buy or trade them through a variety of stock brokers who provide real stock trading services.
According to our data, the recommendation for Entrada Therapeutics shares is from a total of 3 analysts. The average target price prediction is 21 USD per share.
The total number of Entrada Therapeutics shares on the exchange is 37,953,400.00 shares, which at the current market capitalization gives the company a total valuation of 288,445,824.00 USD.
